Trial Profile
Open, Single-center, Phase Ib Study Assessing IBI308 Monotherapy for Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs Sintilimab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions
- 09 May 2022 Results of three year follow up published in the Journal of Thoracic Oncology
- 06 Feb 2020 Results evaluating the safety and outcome of PD-1 inhibitor in neoadjuvant setting published in the Journal of Thoracic Oncology
- 10 Sep 2019 Results (data cut off: June 15th, 2019) assessing the safety and efficacy of neoadjuvant sintilimab in Chinese patients with resectable NSCLCpresented at the 20th World Conference on Lung Cancer